-
JOSH SHIN
Partner·Shanghai
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MR. JOSH SHIN SPECIALIZES IN CORPORATE AND COMMERCIAL LAW MATTERS, WITH EXTENSIVE EXPERIENCES IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCES, PRIVATE EDUCATION AND GENERAL INDUSTRIES SECTORS.
Education
University College London (UCL), Faculty of Law, LL.M
Fudan University, School of Law, LL.B
Professional Qualification
Admitted to practice in the PRC
PROFILE
Mr. Shin maintains a balanced practice between transactional and regulatory advisory matters. Leading the life sciences practice within the firm’s corporate group, Josh is well-versed in advising clients on a wide range of legal matters. He is considered as one of the most active and influential Chinese lawyers in various types of transactions in relevant industries sectors, such as licensing and collaboration and M&A deals. In these transactional works, his "good business sense" and keen understanding of client needs have earned him praise from those he has worked with. Additionally, Mr. Shin has a proven track record in advising clients on regulatory-related issues covering a variety of cutting-edge legal issues. Josh’s clientele commended him that “Finding someone who always has sight of the bigger picture while diving into the smallest details to ensure the quality of work product is not easy. Josh has distinguished himself for his professionalism, enthusiasm to the career and sensitivity of industry.”
REPRESENTATIVE MATTERS AND CASES
- Representing Excalipoint (a Cayman Newco)in securing US$41 million Series A financing (co-led by Hongshan Capital,YuanBio Capital and Apricot Capital), and obtaining the global exclusivelicense for two T-cell engager pipelines from Lepu Biopharma coveringdevelopment, production and commercialization rights.
- Representing AstraZeneca Global Ventures inits equity investments in several China headquartered biotech companies,including FuseBio and SyneronBio.
- Representing AnHeart Therapeutics on itsfull acquisition by Nuvation Bio, a US biopharmaceutical company listed on NYSE(NYSE: NUVB), in an all-stock transaction.
- Representing AnHeart Therapeutics in itscross-border restructuring and Series A+/A-2/B/C equity financing.
- Representing E-Shang Redwood in its seriesacquisitions/disposals of 30+ logistic assets in China.
- Representing AstraZeneca in its investmentof new manufacturing facilities in Qingdao, Taizhou and Wuxi for a total valueof RMB10billion.
- Representing Redwood China Logistics Fundand other sellers in the sale of top tier logistics assets in PRC mainland tothe entity established by ESR and Manulife Financial Group.
- Representing multiple life sciencesstart-ups, such as Cascade, EddingPharm and MitrAssist, in their various roundsof equity financing.
- Representing Eddingpharm on its acquisitionfrom Eli Lilly of the rights for two legacy antibiotic medicines in China:Ceclor and Vancocin, as well as a manufacturing facility in Suzhou.
- Representing Bayer Healthcare China inselling its TCM products and manufacturing plant to a leading Chinapharmaceutical company.
- Representing Education Index Management(the owner of Dulwich College International) in its various rounds privateequity financing and restructuring of its China businss.
- Representing Everbright Holdings in itsinvestment in Shenzhen Lifetech (01302.HK), the leading supplier of minimallyinvasive interventional medical devices to treat cardiovascular diseases.
- Representing Ping’An, ARA, LOGOS, and SunJade Capital in its series acquisitions of logistic assets in China.
- Representing Bayer HealthCare China inreorganization its corporate structure for integration with the onshore part ofMerck OTC Business, following Bayer’s global acquisition of Merck OTCdepartment.
- Representing Bayer AG in its acquisition of100% interest in Dihon Pharmaceutical Group, a leading OTC and traditionalChinese medicine company in China.
- Representing Wuxi AppTec in forming a jointventure with Mayo Clinics regarding advanced medical examination technologies.
- Representing World Strides, the largesteducational travel company in the world, in acquiring summer camping businessin China.
- Representing Parkway Health, a leadinghealthcare services provider in Asia in its investment into several privatehospitals and clinics in various provinces in China.
- Representing Kyowa Kirin in itsAsia-Pacific business restructuring, which involved transferring entireinterest of Kyowa Kirin China to WinHealth Pharma through a series of transactions,while granting WinHealth: Commercialization and production rights in China for fivecommercial-stage originator brand pharmaceuticals, and China commercializationrights for two global products.
- Represented AstraZeneca in multiple combostudy projects with certain biopharma companies including Ascentage Pharma,Wuxi BioCity, Shanghai JMT and Genhouse.
- Represented Duality Bio (9606.HK) ingranting commercialization rights to 3SBio’s subsidiaryShenyang 3SBio for multiple indications of the DB-1303 product (a HER2antibody-drug conjugate) in mainland China, Hong Kong, and Macau.
- Represented TJ Bio to enter into astrategic collaboration with Sanofi for developing, manufacturing andcommercializing the globally innovative asset CD73 monoclonal antibody(Uliledlimab) in Greater China.
- Represented Henlius (2696.HK) in licensingE-602 from Palleon Pharmaceuticals for the Greater China region and in reachinga global collaboration on combo therapy with Palleon Pharmaceuticals.
- Represented CSPC’swholly-owned subsidiary Shanghai JMT-BIO to enter into an exclusive licenseagreement with Jiangsu Alphamab for developing and commercializing JSKN003 (abiparatopic HER2-targeting antibody-drug conjugate/ADC) in Mainland China, withupfront payment plus near-term development milestones amounting to approx.US$100 million.
- Representing Kanghua in granting HilleVaxthe exclusive rights to develop, manufacture and commercialize Kanghua’shexavalent virus-like particle (VLP) vaccine candidate for norovirus in theex-Greater China territory.
- Represented Hengrui Pharmaceuticals in itsout-licensing partnership with Aiolos Bio with respect to Hengrui's innovativeanti-TSLP monoclonal antibody (SHR-1905) in ex-Greater China territory.
- Represented CStone Pharmaceuticals inout-licensing of exclusive development, registration, manufacturing andcommercialization right related to anti-PD-1 monoclonal antibody (nofazinlimab)in mainland China to 3SBio Inc.
- Representing multiple MNCs in exclusivepromotion and/or CSO arrangements with respect to their core products withpartners in China market.
- Representing AstraZeneca in reaching aco-promotion arrangement with Daiichi Sankyo of DS8201 in China marketfollowing a global license of DS8201.
- Representing CStone Pharmaceuticals ingranting the exclusive rights to Hengrui Pharmaceuticals for research,development, registration, manufacturing, and commercialization of anti-CTLA-4mAb CS1002 in the Greater China region.
- Representing medical devices companiesincluding Baxter and Cordis, in connection with its contract design, contractR&D and contract manufacturing transaction in China market.
- Representing OnCusp Therapeutics inobtaining global (ex-China) exclusive license to an ADC drug candidate fromMultitude Therapeutics.
- Representing Anheart Therapeutics, ingranting exclusive commercialization right in PRC market with respect toAnheart’s lead drug candidate taletrectinib, a next-generation tyrosine kinasein¬hibitor (TKI) designed to effectively target ROS1 and NTRK to Innovent, inChina Market and to Nippon Kayaku, a listed company in Japan, in Japan marketrespectively.
- Representing AstraZeneca in granting toBioKangtai the exclusive license in China with respect to the AZD1222, anadenovirus vector-based COVID-19 vaccine initially developed by OxfordUniversity.
- Representing AstraZeneca in obtaining theexclusive promotion rights Luye Pharmaceuticals with respect to Xue Zhi KangCapsule, a first-line blood lipid management drug. This is the first time thata multinational pharmaceutical company has gained exclusive authorization inChina to promote an innovative drug independently developed by a Chinesepharmaceutical company.
- Representing AstraZeneca in its granting ofexclusive commercialization rights to Plendil in China market to China MedicalSystem for an upfront fee of USD310million and ongoing economic sharing.
- Representing AstraZeneca in its granting ofexclusive commercialization rights to certain GLP-1 diabetes drugs in Chinamarket to 3Sbio for an upfront fee of USD100million and ongoing economicsharing.
- Representing Johnson Matthey, Covestro AG,E-Shang Redwood, Education Index Management, Nord Anglia, Celanese and a numberof other companies, in regulatory issues arising from daily business.
- Representing life sciences companiesincluding AstraZeneca, BMS, Brii, AnHeart Therapeutics, Pfizer, Organon, SmithNephew, Vantive, Novartis AG, Boehringer Ingelheim, Roche Pharmaceuticals,C-Stone Pharmaceuticals, Zai Lab, Biogen, Tonghua Dongbao, Duality Bio andHenlius, in regulatory and compliance issues arising from daily business,including research and development projects, clinical trials, responding to investigationand enforcement actions from drug regulating authorities, market authorization,product distribution, PAP/PSP, PBM, product promotion, and NGO/PAG interactions.
- Advising Dulwich College InternationalChina schools, Dehong Chinese International School, Shanghai Concord BilingualSchool and Nord Anglia schools on various legal issues in daily operation,including new school opening, campus construction/expansion, regulatorycompliance, related party transaction, procurement, data protection, schoolmanagement, debt financing, etc.
OTHER INFORMATION
- As a leading industry figure, Josh has been routinely invited to give speeches or participate in panel discussions at professional conferences and forums in different countries, sharing his insights on life sciences industries, BD and M&A transactions, and compliance issues.
- Lead Author “Pharma Legal Handbook - PRC” published by Pharma Boardroom (edition 2019 and 2021).
- Co-author, “China life sciences: Transaction insights and notable industry trends”, Legal 500 (Feb 2024).
- Co-author, “Life Sciences Yearbook 2024: China life sciences Q&A “, Legal 500 (Feb 2024).
- Recommended as leading lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 through 2021 and by Chambers and Partners - Greater China 2022 through 2025.
- Recommended as leading individual for “healthcare and life-science” by Legal 500 –Asia Pacific 2020 through 2024.
- Recommended as distinguished practitioner in Healthcare legal services by Asia Law 2022 and 2024.
- Pharmaceutical, Medical and Biotech M&A Legal Advisor of the Year 2019, by Merger Market.
- Awarded jointly by China Health Consulting and CITIC Securities as “Top 5 Practitioners in Healthcare Sector” in 2023
- Josh has been dedicated to public welfare and the professional growth of young professionals for many years, and is an active contributor and former council member of NGLegal, a youth legal development program.
- Currently serves as Deputy Director of the Legal & Compliance Committee, Shanghai Biopharmaceutical Association
